| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1030726842 |
| P356 | DOI | 10.1007/S12035-008-8031-2 |
| P698 | PubMed publication ID | 18581273 |
| P2093 | author name string | Charles F Albright | |
| Donna M Barten | |||
| P2860 | cites work | Bace1 modulates myelination in the central and peripheral nervous system. | Q53588736 |
| Perspective on a pathogenesis and treatment of Alzheimer's disease. | Q53600765 | ||
| A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease | Q58202813 | ||
| Taxol stabilizes [Ca2+]i and protects hippocampal neurons against excitotoxicity | Q70804531 | ||
| Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer | Q73875834 | ||
| Alzheimer's Disease Pathology in Non-Demented Elderly | Q74736001 | ||
| Inflammatory processes in Alzheimer's disease | Q79557863 | ||
| New Alzheimer's clinical trials to be undertaken by NIA nationwide consortium | Q79745764 | ||
| Antioxidants and Alzheimer's disease: time to stop feeding vitamin E to dementia patients? | Q79799689 | ||
| Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI) | Q79847618 | ||
| List of drugs in development for neurodegenerative diseases. Update June 2006 | Q80217199 | ||
| Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond | Q22251042 | ||
| Forecasting the global burden of Alzheimer’s disease | Q22252403 | ||
| Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice | Q24649564 | ||
| Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice | Q24681736 | ||
| Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics | Q24685475 | ||
| Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage | Q24791704 | ||
| Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model | Q28115206 | ||
| Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo | Q28131779 | ||
| Alzheimer's disease: genes, proteins, and therapy | Q28131806 | ||
| Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies | Q28143521 | ||
| Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization | Q28185520 | ||
| Mitochondria as a target for neurotoxins and neuroprotective agents | Q28186231 | ||
| Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer | Q28207603 | ||
| Tau phosphorylation in Alzheimer's disease: pathogen or protector? | Q28244594 | ||
| The gamma-secretase complex: membrane-embedded proteolytic ensemble | Q28248433 | ||
| Control of peripheral nerve myelination by the beta-secretase BACE1 | Q28264800 | ||
| LTP inhibits LTD in the hippocampus via regulation of GSK3beta | Q28290606 | ||
| Brain inflammation, cholesterol, and glutamate as interconnected participants in the pathology of Alzheimer's disease. | Q36393650 | ||
| Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity | Q36423126 | ||
| Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents | Q36437843 | ||
| Incidence and predictors of seizures in patients with Alzheimer's disease | Q36474116 | ||
| Tau therapeutic strategies for the treatment of Alzheimer's disease | Q36483103 | ||
| Molecular mechanism of neuronal plasticity: induction and maintenance of long-term potentiation in the hippocampus | Q36518791 | ||
| Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer's disease: allopregnanolone as a proof of concept neurogenic agent | Q36536209 | ||
| Autophagy in neurodegenerative disease: friend, foe or turncoat? | Q36543319 | ||
| Statin therapy in Alzheimer's disease | Q36546516 | ||
| Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms | Q36564840 | ||
| Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation | Q28506134 | ||
| Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor | Q28573596 | ||
| Lithium ions: a novel treatment for pheochromocytomas and paragangliomas | Q28582101 | ||
| A specific amyloid-beta protein assembly in the brain impairs memory | Q28854597 | ||
| Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine | Q29465775 | ||
| Alzheimer's disease is a synaptic failure | Q29547670 | ||
| Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria | Q29614408 | ||
| Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function | Q29614851 | ||
| Tau suppression in a neurodegenerative mouse model improves memory function | Q29615831 | ||
| Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model | Q29617937 | ||
| Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse | Q29619237 | ||
| Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders | Q29619537 | ||
| Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease | Q30080016 | ||
| Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease | Q30477260 | ||
| BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. | Q30483997 | ||
| Disrupting beta-amyloid aggregation for Alzheimer disease treatment | Q30829466 | ||
| Disease-modifying therapies for Alzheimer disease: challenges to early intervention | Q31133189 | ||
| Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation | Q32063777 | ||
| Functional outcomes of drug treatment in Alzheimer's disease: A systematic review and meta-analysis | Q33274853 | ||
| Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model | Q33715257 | ||
| Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo | Q33771431 | ||
| Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. | Q33996719 | ||
| Potential compensatory responses through autophagic/lysosomal pathways in neurodegenerative diseases | Q33998034 | ||
| Schizophrenia and the alpha7 nicotinic acetylcholine receptor | Q34002872 | ||
| The galvanization of beta-amyloid in Alzheimer's disease | Q34063386 | ||
| Muscarinic M(1) agonists in the treatment of Alzheimer's disease | Q34075102 | ||
| Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. | Q34082498 | ||
| Cholinesterase inhibitors stabilize Alzheimer's disease | Q34148278 | ||
| Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. | Q34212336 | ||
| Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial | Q34283745 | ||
| Muscarinic agonists and antagonists in the treatment of Alzheimer's disease | Q34290752 | ||
| Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. | Q34417339 | ||
| The cholinergic system in Alzheimer's disease | Q34441061 | ||
| Neuroprotective therapies for Alzheimer's disease | Q34493535 | ||
| Alzheimer's disease and the aging brain | Q34552927 | ||
| Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane | Q34574380 | ||
| Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice | Q48639403 | ||
| Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage | Q48679164 | ||
| Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. | Q48727362 | ||
| Microtubule-stabilising drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments | Q48871501 | ||
| Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. | Q48893777 | ||
| Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation | Q48960635 | ||
| Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits. | Q51810011 | ||
| S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila. | Q52677310 | ||
| Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. | Q52947779 | ||
| Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity. | Q53234286 | ||
| Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. | Q53245545 | ||
| Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. | Q53341838 | ||
| Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine | Q36581239 | ||
| On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease | Q36582363 | ||
| Inflammation in Alzheimer disease: driving force, bystander or beneficial response? | Q36589042 | ||
| Neuronal macroautophagy: from development to degeneration | Q36603384 | ||
| Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds | Q36626447 | ||
| A network dysfunction perspective on neurodegenerative diseases | Q36628146 | ||
| Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications | Q36667507 | ||
| Therapeutic treatments for Alzheimer's disease based on metal bioavailability | Q36679290 | ||
| Pathways by which Abeta facilitates tau pathology | Q36683206 | ||
| The role of tau phosphorylation in the pathogenesis of Alzheimer's disease | Q36683211 | ||
| The role of neurotrophins and insulin on tau pathology in Alzheimer's disease | Q36729493 | ||
| Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease | Q36730365 | ||
| Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties | Q36754766 | ||
| Activity-dependent neuroprotective protein: from gene to drug candidate | Q36760752 | ||
| Endocannabinoids and synaptic function in the CNS. | Q36778581 | ||
| A brief history of tau: the evolving view of the microtubule-associated protein tau in neurodegenerative diseases | Q36784553 | ||
| Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior | Q36822516 | ||
| Nerve growth factor gene delivery: animal models to clinical trials | Q36827338 | ||
| Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. | Q36836607 | ||
| Histamine H3 receptor ligands break ground in a remarkable plethora of therapeutic areas | Q36861579 | ||
| Phenserine | Q36861622 | ||
| Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase | Q36893731 | ||
| Advances in gamma-secretase modulation. | Q36894653 | ||
| Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents | Q36894891 | ||
| Looking for novel ways to treat the hallmarks of Alzheimer's disease | Q36904846 | ||
| One hundred years after the discovery of Alzheimer's disease. A turning point for therapy? | Q36938992 | ||
| Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats | Q36980744 | ||
| Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications | Q37014754 | ||
| Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. | Q38396432 | ||
| Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. | Q38686402 | ||
| Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. | Q39173722 | ||
| Granular tau oligomers as intermediates of tau filaments | Q39202279 | ||
| Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. | Q40005542 | ||
| Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. | Q40090247 | ||
| Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression | Q40240076 | ||
| Intra- or intercomplex binding to the gamma-secretase enzyme. A model to differentiate inhibitor classes | Q40245326 | ||
| Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells | Q40264789 | ||
| Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice | Q40305380 | ||
| Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. | Q40335208 | ||
| The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice | Q40342362 | ||
| Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study | Q40349700 | ||
| Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. | Q40393503 | ||
| Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors | Q40405708 | ||
| Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. | Q40453197 | ||
| Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation | Q40523976 | ||
| Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation | Q40601680 | ||
| Diagnostic criteria for the neuropathologic assessment of Alzheimer's disease | Q41612721 | ||
| Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease | Q41753192 | ||
| Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers | Q41943464 | ||
| Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils | Q43718666 | ||
| A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity | Q43793656 | ||
| Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease | Q43860008 | ||
| Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila | Q44662134 | ||
| BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease | Q44722202 | ||
| Muscarinic M2 antagonists: anthranilamide derivatives with exceptional selectivity and in vivo activity | Q44728395 | ||
| Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial | Q44735780 | ||
| Combination of rimonabant and donepezil prolongs spatial memory duration | Q44926074 | ||
| Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome | Q45007178 | ||
| {beta}-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. | Q45064202 | ||
| Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. | Q46097064 | ||
| Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. | Q46380915 | ||
| Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. | Q46522758 | ||
| Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers | Q46555308 | ||
| Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice | Q46574998 | ||
| Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation. | Q46614986 | ||
| Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration | Q46626629 | ||
| Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. | Q46726652 | ||
| M1 receptors play a central role in modulating AD-like pathology in transgenic mice | Q46737320 | ||
| In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. | Q46835118 | ||
| Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. | Q46899478 | ||
| Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease | Q46966608 | ||
| Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease | Q48007049 | ||
| Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice. | Q48139851 | ||
| Alzheimer-like changes in rat models of spontaneous diabetes | Q48189726 | ||
| Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. | Q48217044 | ||
| Minocycline does not affect amyloid beta phagocytosis by human microglial cells | Q48265471 | ||
| Neurons may live for decades with neurofibrillary tangles | Q48277531 | ||
| Glycogen synthase kinase-3 inhibition is integral to long-term potentiation | Q48301898 | ||
| Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers | Q48326021 | ||
| Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. | Q48363055 | ||
| A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease | Q48379797 | ||
| Macrocyclic inhibitors of beta-secretase: functional activity in an animal model | Q48398864 | ||
| Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease | Q48442778 | ||
| Cerebral hemorrhage after passive anti-Abeta immunotherapy | Q48445999 | ||
| The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation | Q48486318 | ||
| Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. | Q48535203 | ||
| Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis | Q48555329 | ||
| Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model | Q48635943 | ||
| L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors. | Q34574461 | ||
| Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. | Q34626231 | ||
| An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice | Q34687145 | ||
| Small molecule neurotrophin receptor ligands: novel strategies for targeting Alzheimer's disease mechanisms | Q34741499 | ||
| Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology | Q34763076 | ||
| Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5 | Q35084361 | ||
| A clinical overview of cholinesterase inhibitors in Alzheimer's disease. | Q35085193 | ||
| Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers | Q35126030 | ||
| M<sub>1</sub> Muscarinic Agonists Can Modulate Some of the Hallmarks in Alzheimer's Disease: Implications in Future Therapy | Q35538840 | ||
| Distinct presenilin‐dependent and presenilin‐independent γ‐secretases are responsible for total cellular Aβ production | Q35575845 | ||
| The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins | Q35629026 | ||
| Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications | Q35639165 | ||
| Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease | Q35689983 | ||
| Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge | Q35753298 | ||
| Glycogen synthase kinase 3: a drug target for CNS therapies | Q35800094 | ||
| Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies | Q35839667 | ||
| Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors | Q35839729 | ||
| Clearance of Alzheimer's Abeta peptide: the many roads to perdition. | Q35875785 | ||
| Pharmacological inhibitors of glycogen synthase kinase 3. | Q35960333 | ||
| Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. | Q36021972 | ||
| Mitochondrial aging and dysfunction in Alzheimer's disease | Q36082205 | ||
| Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance | Q36157412 | ||
| Neurotrophin receptor-based strategies for Alzheimer's disease | Q36172681 | ||
| The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. | Q36173075 | ||
| 5-HT6 receptors: a novel target for cognitive enhancement | Q36187762 | ||
| Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide | Q36206306 | ||
| Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics | Q36248793 | ||
| Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum | Q36284713 | ||
| Measuring morphological and cellular changes in Alzheimer's dementia: a review emphasizing stereology | Q36296832 | ||
| Phosphodiesterase inhibitors for cognitive enhancement | Q36297630 | ||
| Two sides of the same coin: Wnt signaling in neurodegeneration and neuro-oncology. | Q36321954 | ||
| Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases | Q36337317 | ||
| Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease | Q36342344 | ||
| GABAB receptor: a site of therapeutic benefit | Q36345323 | ||
| P433 | issue | 2-3 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 171-186 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | Molecular Neurobiology | Q15716645 |
| P1476 | title | Therapeutic strategies for Alzheimer's disease | |
| P478 | volume | 37 |
| Q38186705 | Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia |
| Q48428747 | Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease |
| Q30388923 | Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders |
| Q47350221 | Amyloid-Like β-Aggregates as Force-Sensitive Switches in Fungal Biofilms and Infections. |
| Q37576090 | An update on treatment and prevention strategies for Alzheimer's disease |
| Q36995865 | Attenuation of β-amyloid-induced oxidative cell death by sulforaphane via activation of NF-E2-related factor 2. |
| Q40749941 | Countering amyloid polymorphism and drug resistance with minimal drug cocktails |
| Q34646921 | Current and future treatments for Alzheimer's disease |
| Q34067487 | Current treatment and recent clinical research in Alzheimer's disease |
| Q39510974 | Delivery of epidermal neural crest stem cells (EPI-NCSC) to hippocamp in Alzheimer's disease rat model. |
| Q37462620 | Development of vaccination approaches for the treatment of neurological diseases |
| Q33403809 | Discovery of amyloid-beta aggregation inhibitors using an engineered assay for intracellular protein folding and solubility |
| Q35090423 | Disease-modifying treatments for Alzheimer's disease |
| Q89225010 | Dual targeting agents for Aβ plaque/P-glycoprotein and Aβ plaque/nicotinic acetylcholine α4β2* receptors-potential approaches to facilitate Aβ plaque removal in Alzheimer's disease brain |
| Q42315307 | Evaluation of [11C]TAZA for amyloid β plaque imaging in postmortem human Alzheimer's disease brain region and whole body distribution in rodent PET/CT. |
| Q35543238 | Expression of a naturally occurring angiotensin AT(1) receptor cleavage fragment elicits caspase-activation and apoptosis |
| Q50574806 | Human umbilical cord blood-derived monocytes improve cognitive deficits and reduce amyloid-β pathology in PSAPP mice. |
| Q37302816 | Immune-directed gene therapeutic development for Alzheimer's, prion, and Parkinson's diseases |
| Q41831450 | Impact of methionine oxidation as an initial event on the pathway of human prion protein conversion |
| Q35850265 | Lessons from in vitro studies and a related intracellular angiotensin II transgenic mouse model |
| Q37556743 | Membrane topology of gp41 and amyloid precursor protein: interfering transmembrane interactions as potential targets for HIV and Alzheimer treatment. |
| Q42598089 | Memory and neurogenesis in aging and Alzheimer's disease. |
| Q34348499 | Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine-binding site of N-methyl-D-aspartate receptor |
| Q37544750 | Novel strategies for the prevention of dementia from Alzheimer's disease. |
| Q37928994 | Oxidative stress and β-amyloid protein in Alzheimer's disease |
| Q37326505 | Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps |
| Q37952579 | Polyglutamine misfolding in yeast: toxic and protective aggregation |
| Q33943357 | Progress in Alzheimer's disease |
| Q34101110 | Protein aggregation diseases: pathogenicity and therapeutic perspectives |
| Q46034754 | Recent origin and spread of a common Welsh MAPT splice mutation causing frontotemporal lobar degeneration. |
| Q100464393 | Simulations on the dual effects of flavonoids as suppressors of Aβ42 fibrillogenesis and destabilizers of mature fibrils |
| Q42845252 | Site-Activated Chelators Derived from Anti-Parkinson Drug Rasagiline as a Potential Safer and More Effective Approach to the Treatment of Alzheimer’s Disease |
| Q61450742 | Small Multitarget Molecules Incorporating the Enone Moiety |
| Q24605472 | Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders |
| Q33828966 | Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors |
| Q36496535 | The Human Disease-Associated Aβ Amyloid Core Sequence Forms Functional Amyloids in a Fungal Adhesin |
| Q55514434 | The role of phenolic OH groups of flavonoid compounds with H-bond formation ability to suppress amyloid mature fibrils by destabilizing β-sheet conformation of monomeric Aβ17-42. |
| Q24316146 | The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds |
| Q24631757 | The toxicity of amyloid β oligomers |
| Q39605902 | Yeast cell adhesion molecules have functional amyloid-forming sequences |
Search more.